Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 989-993

  Caudill, Jonathan S ^a   Porcher, Julie C ^b   Steensma, David P ^b  

^a Division of Paediatric Haematology/Oncology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

5q syndrome; Alternative splicing; Cdc25c; Cell cycle regulator; MDS

Indexed keywords

CYCLINE; PROTEIN CDC25C; PROTEIN TYROSINE PHOSPHATASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALTERNATIVE PRE RNA SPLICING; ALTERNATIVE RNA SPLICING; ARTICLE; CELL CYCLE REGULATION; CHROMOSOME 5Q; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE LOCATION; GENETIC CONSERVATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; CDC25 PHOSPHATASES; CELL CYCLE; CHROMOSOMES, HUMAN, PAIR 5; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PROTEIN ISOFORMS; RNA PRECURSORS; RNA SPLICING;

EID: 46749151804     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801971690     Document Type: Article

References (14)

1. Matlin, A. J., Clark, F. and Smith, C. W. (2005) Understanding alternative splicing: Towards a cellular code. Nat Rev Mol Cell Biol, 6, pp. 386-398.
2. Novoyatleva, T., Tang, Y., Rafalska, I. and Stamm, S. (2006) Pre-mRNA missplicing as a cause of human disease. Prog Mol Subcell Biol, 44, pp. 27-46.
3. Venables, J. P. (2004) Aberrant and alternative splicing in cancer. Cancer Res, 64, pp. 7647-7654.
4. Karlsson-Rosenthal, C. and Millar, J. B. (2006) Cdc25: Mechanisms of checkpoint inhibition and recovery. Trends Cell Biol, 16, pp. 285-292.
5. Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J. and Loda, M. (1995) CDC25 phosphatases as potential human oncogenes. Science, 269, pp. 1575-1577.
6. Le Gac, G, Esteve, P. O., Ferec, C. and Pradhan, S. (2006) DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem, 281, pp. 24161-24170.
7. Hernandez, S., Hernandez, L., Bea, S., Pinyol, M., Nayach, I. and Bellosillo, B. (2000) cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int J Cancer, 89, pp. 148-152.
8. Wegener, S., Hampe, W., Herrmann, D. and Schaller, H. C. (2000) Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol, 79, pp. 810-815.
9. Baldin, V., Cans, C., Superti-Furga, G. and Ducommun, B. (1997) Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene, 14, pp. 2485-2495.
10. Ozen, M. and Ittmann, M. (2005) Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res, 11, pp. 4701-4706.
11. Boultwood, J., Fidler, C., Strickson, A. J., Watkins, F., Gama, S. and Kearney, L. (2002) Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood, 99, pp. 4638-4641.
12. List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D. and Fuchs, D. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 352, pp. 549-557.
13. Steensma, D. P., Gibbons, R. J. and Higgs, D. R. (2005) Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood, 105, pp. 443-452.
14. Chen, M. S., Hurov, J., White, L. S., Woodford-Thomas, T. and Piwnica-Worms, H. (2001) Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol Cell Biol, 21, pp. 3853-3861.